Eli Lilly Completes Acquisition of Point Biopharma, Expanding Radiopharmaceutical Portfolio
Eli Lilly (NYSE: LLY) has finalized its acquisition of radiopharmaceutical company Point Biopharma (NASDAQ: PNT)...
Fosun’s HLX42 Receives Fast-Track Designation from FDA for NSCLC Treatment
Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196; SHA: 600196) has announced that its antibody-drug conjugate...
CATUG Biotechnology Partners with PersonGen to Advance Global CAR-T Cell Therapies
China-based CATUG Biotechnology (Suzhou) Co., Ltd. has entered into a partnership with fellow Suzhou firm...
Cryofocus Medtech Secures NMPA Approval for Cryotherapy Equipmen
Shanghai-based Cryofocus Medtech (Shanghai) Co., Ltd. (HKG: 6922) has announced that it has received marketing...
Simcere Secures Approval for Local Manufacturing of Cosela, Boosting Patient Access
China-based Simcere Pharmaceutical Group (HKG: 2096) has received supplementary filing approval for its drug Cosela...
Chengda Pharmaceuticals Halts Shanghai Research Project Amid Market Challenges
Chengda Pharmaceuticals Co. Ltd. (SHE: 301201), based in China, has announced the termination of its...
TYK Medicines Secures Nearly RMB 200 Million in Series D Financing Led by Sichuan Huiyu Pharmaceutical
Shanghai-based TYK Medicines (HKG: 2410) has successfully completed a Series D financing round, raising nearly...
NMPA Approves Pulnovo Medical’s Novel Catheter for Treating Pulmonary Arterial Hypertension
The National Medical Products Administration (NMPA) has granted marketing approval for Pulnovo Medical’s disposable circular...
Innovent Biologics Partners with Xuanzhu Biopharma for Clinical Trial of Sintilimab and KM-501 in Advanced Tumors
Innovent Biologics, Inc. (HKG: 1801), based in China, has entered into a clinical trial collaboration...
Sanofi Gains NMPA Approval for Innovative Rosuvastatin and Ezetimibe Combination Therapy
Sanofi (NASDAQ: SNY), the French pharmaceutical giant, has announced that it has received market approval...
Janssen Acquires Rights to Gene Therapy Botaretigene Sparoparvovec from MeiraGTx for XLRP Treatment
Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson (J&J, NYSE: JNJ), announced last week its...
AstraZeneca Secures FDA Approval for Self-Administered hATTR-PN Therapy Wainua
AstraZeneca (AZ, NASDAQ: AZN), headquartered in the UK, announced last week that the U.S. Food...
Elpiscience Partners with Astellas for Bi-Specific Macrophage Engager Research
China-based Elpiscience Biopharmaceuticals has announced a research collaboration and licensing agreement with Japan’s Astellas Pharma...
Panlin Capital Raises Second Fund Focused on Biopharmaceutical Innovation
Panlin Capital has announced the successful closing of its second venture capital fund, the Hangzhou...
XRGenesis Raises $14 Million in Series A to Advance Ophthalmic Surgical Technology
XRGenesis, a developer of high-end ophthalmic surgical equipment based in Hangzhou, has reportedly raised nearly...
Taiwan FDA Reviews Nefecon New Drug Application from Everest Medicines
China-based Everest Medicines (HKG: 1952) has announced that the New Drug Application (NDA) for Nefecon...
J&J’s Janssen Secures Exclusive Global Rights to Develop LCB84 ADC from LegoChem Biosciences
Johnson & Johnson’s (J&J; NYSE: JNJ) pharmaceutical subsidiary, Janssen, has entered into an exclusive global...
BMS Expands Oncology Portfolio with $4.1 Billion RayzeBio Acquisition
Bristol Myers Squibb (BMS; NYSE: BMY) has announced the acquisition of RayzeBio (NASDAQ: RYZB), a...
Amgen’s Lumakras Faces Full Approval Delay as FDA Requests New Study
The US Food and Drug Administration (FDA) has declined to grant full approval for Amgen’s...
China’s NMPA Proposes Enhanced IT and Visualization Requirements for Blood Product GMP
The National Medical Products Administration (NMPA) of China is currently soliciting public feedback on the...